Global Study on Rilvegostomig or Pembrolizumab for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Inclusion Criteria

• Diagnosed with non-small cell lung cancer (NSCLC), including all types.
• Cancer has spread to other parts of the body (Stage IV) and cannot be treated with surgery.
• No specific genetic mutations that have targeted treatments available.
• Good overall health with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Expected to live at least 12 more weeks.
• Able to provide a tumor sample for testing.
• Have at least one tumor that can be measured accurately with scans.
• Have good organ and bone marrow function.

Exclusion Criteria

• Have severe or uncontrolled health conditions that could interfere with the study.
• Have had an organ transplant.
• Have autoimmune or inflammatory disorders needing long-term steroid or immunosuppressive treatment.
• Have had another cancer unless it was treated and inactive for at least 2 years.
• Have small cell or neuroendocrine cancer types.
• Have brain metastases unless they are stable and not needing treatment for at least 4 weeks.
• Have active immune system deficiencies or infections.
• Have active tuberculosis.
• Have received any previous treatment for advanced or metastatic NSCLC.
• Have been treated with anti-TIGIT or other immune-targeting therapies.
• Have been treated with anti-PD-1 or anti-PD-L1 therapies before.